{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:31:48Z","timestamp":1791477108306,"version":"4.3.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz Group AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Diakonhjemmet Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40259-025-00727-z","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T13:41:05Z","timestamp":1749130865000},"page":"537-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-3093","authenticated-orcid":false,"given":"Tore K.","family":"Kvien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-1158","authenticated-orcid":false,"given":"Neil","family":"Betteridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Br\u00fcckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Bodenm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galyna","family":"Bryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6263-0313","authenticated-orcid":false,"given":"Zorana","family":"Maravic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-190X","authenticated-orcid":false,"given":"Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0298-6948","authenticated-orcid":false,"given":"Laura","family":"Wingate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-7873","authenticated-orcid":false,"given":"Paul","family":"Cornes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"727_CR1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/jamaoncol.2021.7230","volume":"8","author":"D Bloomfield","year":"2022","unstructured":"Bloomfield D, D\u2019Andrea E, Nagar S, Kesselheim A. Characteristics of clinical trials evaluating biosimilars in the treatment of cancer: a systematic review and meta-analysis. JAMA Oncol. 2022;8:537\u201345.","journal-title":"JAMA Oncol"},{"key":"727_CR2","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. 2014. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 16 Jan 2025."},{"key":"727_CR3","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1001\/jama.2017.5202","volume":"317","author":"A Hakim","year":"2017","unstructured":"Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. JAMA. 2017;317:2163\u20134.","journal-title":"JAMA"},{"key":"727_CR4","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/art.41203","volume":"72","author":"J Yazdany","year":"2020","unstructured":"Yazdany J. Failure to launch: biosimilar sales continue to fall flat in the United States. Arthritis Rheumatol. 2020;72:870\u20133.","journal-title":"Arthritis Rheumatol"},{"key":"727_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52: 151939.","journal-title":"Semin Arthritis Rheum"},{"key":"727_CR6","unstructured":"IQVIA. Impact of biosimilar competition report 2024 - European Commission 8th Biosimilar Multistakeholder Event. 2024. https:\/\/health.ec.europa.eu\/events\/biosimilar-medicines-multistakeholder-event-2024-12-05_en. Accessed 16 Jan 2025."},{"key":"727_CR7","first-page":"3","volume":"7","author":"AW Mulcahy","year":"2018","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7:3.","journal-title":"Rand Health Q."},{"key":"727_CR8","unstructured":"Fronstin P, Roebuck MC. Location, location, location: spending differences for biologic and biosimilar medications by site of treatment. 2023. https:\/\/www.ebri.org\/docs\/default-source\/ebri-issue-brief\/ebri_ib_585_biologicbiosimilar-29june23.pdf?sfvrsn=d9de392f_2. Accessed 16 Jan 2025."},{"key":"727_CR9","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1186\/s12889-019-7762-5","volume":"19","author":"P Maresova","year":"2019","unstructured":"Maresova P, Javanmardi E, Barakovic S, et al. Consequences of chronic diseases and other limitations associated with old age - a scoping review. BMC Public Health. 2019;19:1431.","journal-title":"BMC Public Health"},{"key":"727_CR10","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.5888\/pcd18.210006","volume":"18","author":"HK Weir","year":"2021","unstructured":"Weir HK, Thompson TD, Stewart SL, White MC. Cancer incidence projections in the United States between 2015 and 2050. Prev Chronic Dis. 2021;18:E59.","journal-title":"Prev Chronic Dis"},{"key":"727_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","volume":"18","author":"I Soerjomataram","year":"2021","unstructured":"Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020\u20132070. Nat Rev Clin Oncol. 2021;18:663\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"727_CR12","doi-asserted-by":"publisher","first-page":"iv49","DOI":"10.1093\/rheumatology\/kex276","volume":"56","author":"T Uhlig","year":"2017","unstructured":"Uhlig T, Goll GL. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56:iv49-62.","journal-title":"Rheumatology (Oxford)"},{"key":"727_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.7861\/futurehosp.5-2-88","volume":"5","author":"F Mortimer","year":"2018","unstructured":"Mortimer F, Isherwood J, Wilkinson A, Vaux E. Sustainability in quality improvement: redefining value. Future Healthc J. 2018;5:88\u201393.","journal-title":"Future Healthc J."},{"key":"727_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","volume":"80","author":"H Kim","year":"2020","unstructured":"Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80:99\u2013113.","journal-title":"Drugs"},{"key":"727_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/ph14020117","volume":"14","author":"Y Vandenplas","year":"2021","unstructured":"Vandenplas Y, Simoens S, Van Wilder P, Vulto AG, Huys I. Informing patients about biosimilar medicines: the role of European patient associations. Pharmaceuticals (Basel). 2021;14:117.","journal-title":"Pharmaceuticals (Basel)"},{"key":"727_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5639\/gabij.2015.0402.018","volume":"4","author":"A Mack","year":"2015","unstructured":"Mack A. Norway, biosimilars in different funding systems. What works? GaBI Journal. 2015;4:90\u20132.","journal-title":"GaBI Journal."},{"key":"727_CR17","unstructured":"GaBI online. Biosimilars approved in Europe. 2025. https:\/\/www.gabionline.net\/biosimilars\/general\/biosimilars-approved-in-europe. Accessed 2 Apr 2025."},{"key":"727_CR18","unstructured":"GaBI online. Biosimilars approved in the US. 2025. https:\/\/www.gabionline.net\/biosimilars\/general\/biosimilars-approved-in-the-us. Accessed 2 Apr 2025."},{"key":"727_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304851","volume":"19","author":"HH Chen","year":"2024","unstructured":"Chen HH, Yemeke T, Ozawa S. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012\u201319. PLoS ONE. 2024;19: e0304851.","journal-title":"PLoS ONE"},{"key":"727_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429","volume":"5","author":"K Feng","year":"2024","unstructured":"Feng K, Russo M, Maini L, Kesselheim AS, Rome BN. Patient out-of-pocket costs for biologic drugs after biosimilar competition. JAMA Health Forum. 2024;5: e235429.","journal-title":"JAMA Health Forum."},{"key":"727_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","volume":"34","author":"B Dutta","year":"2020","unstructured":"Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34:159\u201370.","journal-title":"BioDrugs"},{"key":"727_CR22","unstructured":"IMS Institute for Healthcare Informatics. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets. 2016. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/delivering-on-the-potential-of-biosimilar-medicines.pdf. Accessed 16 Jan 2025."},{"key":"727_CR23","unstructured":"Medicines for Europe. Policy recommendations on uptake of biosimilar medicines in the retail market. 2021. https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2021\/10\/Policy%20recommendations%20on%20uptake%20of%20biosimilar%20medicines%20in%20the%20retail%20market.pdf. Accessed 16 Jan 2025."},{"key":"727_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/CEOR.S140063","volume":"9","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. Clinicoecon Outcomes Res. 2017;9:573\u201384.","journal-title":"Clinicoecon Outcomes Res."},{"key":"727_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10198-023-01580-z","volume":"24","author":"F Antonanzas","year":"2023","unstructured":"Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R. Tenders for generics and biosimilars: a challenging purchasing policy. Eur J Health Econ. 2023;24:485\u20137.","journal-title":"Eur J Health Econ"},{"key":"727_CR26","doi-asserted-by":"publisher","first-page":"1263472","DOI":"10.3389\/fpubh.2024.1263472","volume":"12","author":"S Machado","year":"2024","unstructured":"Machado S, Cruz A, Ferreira PL, Morais C, Pimenta RE. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review. Front Public Health. 2024;12:1263472.","journal-title":"Front Public Health"},{"key":"727_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2024-eular.3590","volume":"83","author":"SA Bergstra","year":"2024","unstructured":"Bergstra SA, Mongin D, Dreyer L, et al. POS0597 Global disparities in biosimilar uptake in patients with rheumatoid arthritis. Ann Rheum Dis. 2024;83:817\u20138.","journal-title":"Ann Rheum Dis"},{"key":"727_CR28","first-page":"699","volume":"9","author":"SM Tinsley","year":"2018","unstructured":"Tinsley SM, Grande C, Olson K, Plato L, Jacobs I. Potential of biosimilars to increase access to biologics: considerations for advanced practice providers in oncology. J Adv Pract Oncol. 2018;9:699\u2013716.","journal-title":"J Adv Pract Oncol"},{"key":"727_CR29","unstructured":"National Institute for Health and Care Excellence. NICE recommends several treatment options to help with rheumatoid arthritis. 2021. https:\/\/www.nice.org.uk\/news\/article\/nice-recommends-several-treatment-options-to-help-with-rheumatoid-arthritis. Accessed 16 Jan 2025."},{"key":"727_CR30","unstructured":"National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. 2016. https:\/\/www.nice.org.uk\/guidance\/ta375. Accessed 16 Jan 2025."},{"key":"727_CR31","first-page":"161","volume":"2","author":"B Heidari","year":"2011","unstructured":"Heidari B. Rheumatoid arthritis: early diagnosis and treatment outcomes. Caspian J Intern Med. 2011;2:161\u201370.","journal-title":"Caspian J Intern Med"},{"key":"727_CR32","unstructured":"Medicines, Diagnostics and Personalised Medicine Policy Team, National Medical Directorate, NHS England. Commissioning framework for biological medicines (including biosimilar medicines). 2017. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2017\/09\/biosimilar-medicines-commissioning-framework.pdf. Accessed 16 Jan 2025."},{"key":"727_CR33","unstructured":"NHS England. The NHS saves \u00a3324 million in a year by switching to better value medicines. 2018. https:\/\/www.england.nhs.uk\/2018\/07\/nhs-saves-324-million-year-switching-to-better-value-medicines\/. Accessed 16 Jan 2025."},{"key":"727_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k461","volume":"360","author":"N Hawkes","year":"2018","unstructured":"Hawkes N. New cancer drugs fund keeps within \u00a3340m a year budget. BMJ. 2018;360: k461.","journal-title":"BMJ"},{"key":"727_CR35","unstructured":"IQVIA. Global oncology trends 2019: therapeutics, clinical development and health system implications. 2019. https:\/\/intelligencepharma.files.wordpress.com\/2019\/05\/global-oncology-trends-2019-report.pdf. Accessed 16 Jan 2025."},{"key":"727_CR36","unstructured":"NHS England. Cancer Drugs Fund activity update Q2 2023-24. 2023. https:\/\/www.england.nhs.uk\/long-read\/cancer-drugs-fund-activity-update-q2-2023-24\/. Accessed 16 Jan 2025."},{"key":"727_CR37","unstructured":"National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. 2018. https:\/\/www.nice.org.uk\/guidance\/ta554. Accessed 16 Jan 2025."},{"key":"727_CR38","unstructured":"Nawrat A. NICE recommends NHS use of Kymriah for second indication. 2019. https:\/\/www.pharmaceutical-technology.com\/news\/nice-nhs-kymriah-second-indication-dlbcl\/. Accessed 16 Jan 2025."},{"key":"727_CR39","unstructured":"NHS England. NHS England announces groundbreaking new personalised therapy for children with cancer. 2018. https:\/\/www.england.nhs.uk\/2018\/09\/nhs-england-announces-groundbreaking-new-personalised-therapy-for-children-with-cancer\/. Accessed 16 Jan 2025."},{"key":"727_CR40","unstructured":"Medicines for Europe. Filling the gap. https:\/\/www.medicinesforeurope.com\/docs\/Filling-the-gap.pdf. Accessed 16 Jan 2025."},{"key":"727_CR41","first-page":"690","volume":"11","author":"V Razanskaite","year":"2017","unstructured":"Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11:690\u20136.","journal-title":"J Crohns Colitis"},{"key":"727_CR42","unstructured":"European Specialist Nurses Organisations. Switch management between similar biological medicines. A communication and information guide for nurses. 2018. https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2018\/06\/biosimilar-nurses-guideline-final.pdf. Accessed 16 Jan 2025."},{"key":"727_CR43","unstructured":"Read C. Specialist nurses support cost effective drugs for treatment. 2017. https:\/\/www.hsj.co.uk\/interactive\/specialist-nurses-support-cost-effective-drugs-for-treatment\/7015632.article. Accessed 16 Jan 2025."},{"key":"727_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/annrheumdis-2013-204020","volume":"74","author":"AB Aga","year":"2015","unstructured":"Aga AB, Lie E, Uhlig T, et al. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000\u20132010. Ann Rheum Dis. 2015;74:381\u20138.","journal-title":"Ann Rheum Dis"},{"key":"727_CR45","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00393-022-01259-5","volume":"82","author":"F H\u00f6rbrand","year":"2023","unstructured":"H\u00f6rbrand F, Schuch F, Bless HH, Messinger D, Bretthauer B, Killian P. PHARAO study: drug treatment of inflammatory rheumatic diseases: guideline-conform treatment with biologics follows availability of biosimilars. Z Rheumatol. 2023;82:787\u201397.","journal-title":"Z Rheumatol"},{"key":"727_CR46","unstructured":"Simon-Kucher and Partners. Payers\u2019 price & market access policies supporting a sustainable biosimilar medicines market. 2016. https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2016\/09\/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication.pdf. Accessed 16 Jan 2025."},{"key":"727_CR47","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/14712598.2023.2273938","volume":"23","author":"GL Goll","year":"2023","unstructured":"Goll GL, Kvien TK. Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway. Expert Opin Biol Ther. 2023;23:1203\u20139.","journal-title":"Expert Opin Biol Ther"},{"key":"727_CR48","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","volume":"75","author":"T Dorner","year":"2016","unstructured":"Dorner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974\u201382.","journal-title":"Ann Rheum Dis"},{"key":"727_CR49","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jamainternmed.2020.0338","volume":"180","author":"TB Jensen","year":"2020","unstructured":"Jensen TB, Kim SC, Jimenez-Solem E, Bartels D, Christensen HR, Andersen JT. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180:902\u20133.","journal-title":"JAMA Intern Med"},{"key":"727_CR50","unstructured":"GaBi Online. Australia approves first biosimilar filgrastim. 2010. https:\/\/www.gabionline.net\/biosimilars\/news\/Australia-approves-first-biosimilar-filgrastim. Accessed 16 Jan 2025."},{"key":"727_CR51","unstructured":"Australian Government Department of Health and Aged Care. Pharmaceutical benefits scheme \u2013 biosimilar filgrastim. https:\/\/www.health.gov.au\/sites\/default\/files\/2024-02\/biosimilar-medicine-fact-sheet-filgrastim.pdf. Accessed 16 Jan 2025."},{"key":"727_CR52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ajco.13337","volume":"16","author":"GP Gregory","year":"2020","unstructured":"Gregory GP, Carrington C, Cheah CY, et al. A consensus statement on the use of biosimilar medicines in hematology in Australia. Asia Pac J Clin Oncol. 2020;16:211\u201321.","journal-title":"Asia Pac J Clin Oncol"},{"key":"727_CR53","unstructured":"Pharmaceutical Management Agency. PHARMAC annual review. 2014. https:\/\/pharmac.govt.nz\/assets\/annual-review-2014.pdf. Accessed 16 Jan 2025."},{"key":"727_CR54","unstructured":"Biosimilars Canada. Saskatchewan becomes sixth province to implement biosimilar switching initiative. 2022. https:\/\/biosimilarscanada.ca\/blog\/saskatchewan-becomes-sixth-province-to-implement-biosimilar-switching-initiative\/. Accessed 16 Jan 2025."},{"key":"727_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41927-021-00235-x","volume":"6","author":"A Fisher","year":"2022","unstructured":"Fisher A, Kim JD, Carney G, Dormuth C. Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept-a cohort study in British Columbia. BMC Rheumatol. 2022;6:5.","journal-title":"BMC Rheumatol."},{"key":"727_CR56","unstructured":"Canadian Digestive Health Foundation. BC Biosimilars Initiative: Phase Two Information. 2023. https:\/\/cdhf.ca\/en\/bc-biosimilars-initiative-phase-two-information\/. Accessed 16 Jan 2025."},{"key":"727_CR57","unstructured":"Welch A. How Canada built a framework for biosimilar transitions in its provinces. 2020. https:\/\/www.biosimilardevelopment.com\/doc\/how-canada-built-a-framework-for-biosimilar-transitions-in-its-provinces-0001. Accessed 16 Jan 2025."},{"key":"727_CR58","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/art.41277","volume":"72","author":"JF Baker","year":"2020","unstructured":"Baker JF, Leonard CE, Lo Re III V, Weisman MH, George MD, Kay J. Biosimilar uptake in academic and veterans health administration settings: influence of institutional incentives. Arthritis Rheumatol. 2020;72:1067\u201371.","journal-title":"Arthritis Rheumatol"},{"key":"727_CR59","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/art.41280","volume":"72","author":"GL Goll","year":"2020","unstructured":"Goll GL, Kvien TK. An opportunity missed: biosimilars in the United States. Arthritis Rheumatol. 2020;72:1046\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"727_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40259-021-00510-w","volume":"36","author":"B Bhardwaja","year":"2022","unstructured":"Bhardwaja B, Klocke S, Ekinci E, Jackson A, Kono S, Olson KL. Switching from biologic to biosimilar products: Insight from an integrated health care system. BioDrugs. 2022;36:1\u201311.","journal-title":"BioDrugs"},{"key":"727_CR61","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2217\/fon-2021-1584","volume":"18","author":"SZ Humphreys","year":"2022","unstructured":"Humphreys SZ. Real-world evidence of a successful biosimilar adoption program. Future Oncol. 2022;18:1997\u20132006.","journal-title":"Future Oncol"},{"key":"727_CR62","unstructured":"GaBI online. Biosimilars approved in Brazil. 2022. https:\/\/gabionline.net\/biosimilars\/general\/biosimilars-approved-in-brazil. Accessed 16 Jan 2025."},{"key":"727_CR63","unstructured":"Minist\u00e9rio da Sa\u00fade, Brasil. Protocolo cl\u00ednico e diretrizes terap\u00eauticas da psor\u00edase. 2020. https:\/\/psoriasebrasil.org.br\/wp-content\/uploads\/2021\/01\/PCDT-DA-PSORIASE-2020.pdf. Accessed 16 Jan 2025."},{"key":"727_CR64","unstructured":"Intercontinental Marketing Services Health Inc. IMS PADDS monthly database July 23 update. 2023. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/available-iqvia-data\/ims-health-market-research-and-reports-repository. Accessed 16 Jan 2025."},{"key":"727_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000010","volume":"1","author":"G Castaneda-Hernandez","year":"2015","unstructured":"Castaneda-Hernandez G, Gonzalez-Ramirez R, Kay J, Scheinberg MA. Biosimilars in rheumatology: what the clinician should know. RMD Open. 2015;1: e000010.","journal-title":"RMD Open"},{"key":"727_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.625296","volume":"12","author":"S Vogler","year":"2021","unstructured":"Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12: 625296.","journal-title":"Front Pharmacol"},{"key":"727_CR67","doi-asserted-by":"crossref","unstructured":"Barcina Lacosta T, Vulto AG, Turcu-Stiolica A, Huys I, Simoens S. Qualitative analysis of the design and implementation of benefit-sharing programs for biologics across europe. biodrugs. 2022;36:217\u201329.","DOI":"10.1007\/s40259-022-00523-z"},{"key":"727_CR68","doi-asserted-by":"crossref","unstructured":"Barcina Lacosta T, Vulto AG, Huys I, Simoens S. An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain. Front Med (Lausanne). 2022;9:1029040.","DOI":"10.3389\/fmed.2022.1029040"},{"key":"727_CR69","doi-asserted-by":"crossref","unstructured":"Lobo F, R\u00edo-\u00c1lvarez I. Barriers to biosimilar prescribing incentives in the context of clinical governance in Spain. Pharmaceuticals (Basel). 2021;14:283.","DOI":"10.3390\/ph14030283"},{"key":"727_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14737167.2023.2146579","volume":"23","author":"J Perelman","year":"2023","unstructured":"Perelman J, Duarte-Ramos F, Melo Gouveia A, et al. How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015\u20132021. Expert Rev Pharmacoecon Outcomes Res. 2023;23:99\u2013109.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"727_CR71","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304\u201316.","journal-title":"Lancet"},{"key":"727_CR72","doi-asserted-by":"publisher","first-page":"13699","DOI":"10.1038\/s41598-023-40222-5","volume":"13","author":"AB de Oliveira","year":"2023","unstructured":"de Oliveira AB, Almeida MO, de Medeiros-Ribeiro AC, de Oliveira Andrade DC, de Oliveira Junior HA, de Soarez PC. Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis. Sci Rep. 2023;13:13699.","journal-title":"Sci Rep"},{"key":"727_CR73","doi-asserted-by":"crossref","unstructured":"Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78:192\u2013200.","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"727_CR74","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/annrheumdis-2023-eular.3343","volume":"82","author":"D Lacaille","year":"2023","unstructured":"Lacaille D, Avi\u00f1a-Zubieta JA, Zheng Y, Lu N, Xie H. POS0566 Survival on treatment after switching to a biosimilar: population-based evidence from a natural experiment due to a policy change. Ann Rheum Dis. 2023;82:551\u20132.","journal-title":"Ann Rheum Dis"},{"key":"727_CR75","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1093\/ibd\/izaa364","volume":"27","author":"S Mahmmod","year":"2021","unstructured":"Mahmmod S, Schultheiss JPD, van Bodegraven AA, et al. Outcome of reverse switching from CT-P13 to originator infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1954\u201362.","journal-title":"Inflamm Bowel Dis"},{"key":"727_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292231","volume":"18","author":"TM Herndon","year":"2023","unstructured":"Herndon TM, Ausin C, Brahme NN, et al. Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis. PLoS ONE. 2023;18: e0292231.","journal-title":"PLoS ONE"},{"key":"727_CR77","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40264-023-01371-8","volume":"46","author":"S Sagi","year":"2023","unstructured":"Sagi S, Anjaneya P, Kalsekar S, Kottke A, Cohen HP. Long-term real-world post-approval safety data of multiple biosimilars from one marketing-authorization holder after more than 18 years since their first biosimilar launch. Drug Saf. 2023;46:1391\u2013404.","journal-title":"Drug Saf"},{"key":"727_CR78","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40259-020-00433-y","volume":"34","author":"HP Cohen","year":"2020","unstructured":"Cohen HP, McCabe D. The Importance of countering biosimilar disparagement and misinformation. BioDrugs. 2020;34:407\u201314.","journal-title":"BioDrugs"},{"key":"727_CR79","doi-asserted-by":"publisher","first-page":"1188368","DOI":"10.3389\/fphar.2023.1188368","volume":"14","author":"KA Alnaqbi","year":"2023","unstructured":"Alnaqbi KA, Bellanger A, Brill A, et al. An international comparative analysis and roadmap to sustainable biosimilar markets. Front Pharmacol. 2023;14:1188368.","journal-title":"Front Pharmacol"},{"key":"727_CR80","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/ph13110400","volume":"13","author":"AG Vulto","year":"2020","unstructured":"Vulto AG, Vanderpuye-Orgle J, van der Graaff M, et al. Sustainability of biosimilars in Europe: a Delphi panel consensus with systematic literature review. Pharmaceuticals (Basel). 2020;13:400.","journal-title":"Pharmaceuticals (Basel)"},{"key":"727_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.37757\/MR2017.V19.N4.4","volume":"19","author":"N Ledon","year":"2017","unstructured":"Ledon N, Lage-Davila A. Biosimilars and the real world. MEDICC Rev. 2017;19:9.","journal-title":"MEDICC Rev"},{"key":"727_CR82","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40259-019-00377-y","volume":"33","author":"E Wolff-Holz","year":"2019","unstructured":"Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33:621\u201334.","journal-title":"BioDrugs"},{"key":"727_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000142","volume":"1","author":"J Tabernero","year":"2016","unstructured":"Tabernero J, Vyas M, Giuliani R, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2016;1: e000142.","journal-title":"ESMO Open."},{"key":"727_CR84","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J Kay","year":"2018","unstructured":"Kay J, Schoels MM, Dorner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165\u201374.","journal-title":"Ann Rheum Dis"},{"key":"727_CR85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjw198","volume":"11","author":"S Danese","year":"2017","unstructured":"Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017;11:26\u201334.","journal-title":"J Crohns Colitis"},{"key":"727_CR86","unstructured":"US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product. 2019. https:\/\/www.fda.gov\/media\/124907\/download. Accessed 16 Jan 2025."},{"key":"727_CR87","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40259-020-00422-1","volume":"34","author":"M Schiestl","year":"2020","unstructured":"Schiestl M, Ranganna G, Watson K, et al. The path towards a tailored clinical biosimilar development. BioDrugs. 2020;34:297\u2013306.","journal-title":"BioDrugs"},{"key":"727_CR88","unstructured":"US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product: Update. 2024. https:\/\/www.fda.gov\/media\/179456\/download. Accessed 16 Jan 2025."},{"key":"727_CR89","unstructured":"Congress.gov. S.2305 - Biosimilar Red Tape Elimination Act. 2023. https:\/\/www.congress.gov\/bill\/118th-congress\/senate-bill\/2305\/text. Accessed 16 Jan 2025."},{"key":"727_CR90","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S2665-9913(23)00268-0","volume":"6","author":"GL Goll","year":"2024","unstructured":"Goll GL, Kvien TK. Biosimilar tocilizumab-better access and lower cost? Lancet Rheumatol. 2024;6:e6\u20138.","journal-title":"Lancet Rheumatol."},{"key":"727_CR91","unstructured":"Eckford C. First European ustekinumab biosimilar to Stelara approved. 2024. https:\/\/www.europeanpharmaceuticalreview.com\/news\/190903\/first-european-ustekinumab-biosimilar-to-stelara-approved\/. Accessed 16 Jan 2025."},{"key":"727_CR92","unstructured":"CADTH. CADTH Canadian Drug Expert Committee Recommendation. 2020. https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0627%20Stelara%20-%20CDEC%20Final%20Recommendation%20July%2020%2C%202020_for%20posting.pdf. Accessed 16 Jan 2025."},{"key":"727_CR93","unstructured":"National Institute for Health and Care Excellence. Ustekinumab for the treatment of adults with moderate to severe psoriasis. 2009. https:\/\/www.nice.org.uk\/guidance\/ta180\/chapter\/4-consideration-of-the-evidence. Accessed 16 Jan 2025."},{"key":"727_CR94","unstructured":"European Medicines Agency. Download medicine data. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/download-medicine-data#european-public-assessment-reports. Accessed 2 Apr 2025."},{"key":"727_CR95","unstructured":"US Food and Drug Administration. Biosimilar product information. 2025. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information. Accessed 2 Apr 2025."},{"key":"727_CR96","unstructured":"Cencora. Biosimilars pipeline report: a guide for understanding the growing market. 2025. https:\/\/www.amerisourcebergen.com\/insights\/manufacturers\/biosimilar-pipeline-report. Accessed 16 Jan 2025."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00727-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00727-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00727-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:03:46Z","timestamp":1750676626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00727-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00727-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"5 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.K.K. reports fees for speaking and\/or consulting from AbbVie, Amgen, Celltrion, Egis, Ewopharma, Gilead, Hikma, Janssen, Mylan, Novartis, Oktal, Pfizer, Sandoz, and UCB; and research funding from AbbVie, BMS, Galapagos, MSD, Novartis, Pfizer, and UCB. N.B. declares consultancy fees received from EULAR, Galapagos, Grunenthal, and Sanofi. I.B., W.B., and G.B. are employees of Sandoz. S.D. declares consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals, Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB, and Vifor; and speaker fees from AbbVie, Amgen, Dr Falk Pharma, Ferring Pharmaceuticals, Gilead, Janssen, Mylan, Pfizer, and Takeda. J.G.\u00a0declares speaker fees from AstraZeneca, Celltrion, Chiesi, Sandoz, and Sanofi. Z.M. has no conflicts of interest to declare. C.T. declares consultancy fees received from Biogen, Nordic, Pfizer, and Sandoz; advisory board fees from AbbVie, Nordic, Pfizer, Roche, and Sandoz; and research grants from Jamp and Pfizer. L.W.\u00a0declares advisory fees received from Act4Biosimilars and PAN Therapeutics. P.C. declares speaker fees from Celltrion, Viatris (formerly Mylan), Pfizer, Novartis, and Sandoz.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was funded by Sandoz Group AG. The funder had a role in the study design, data collection, data analysis, and manuscript preparation. The open access fee was also sponsored by Sandoz Group AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent to Participate\/Publish"}},{"value":"Data available on request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"I.B., W.B., and G.B. contributed to the study design, literature search, and data analysis. N.B., Z.M., C.T., and L.W. contributed to the study design, data analysis, and manuscript development. T.K.K., J.G., and P.C. contributed to the study design and manuscript development. All authors were involved in the preparation and review of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}